Columbia Laboratories, Inc. (CBRX) Tops Q2 EPS Views
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Columbia Laboratories, Inc. (NASDAQ: CBRX) reported Q2 EPS of $0.16, $0.17 better than the analyst estimate of ($0.01).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SunTrust Banks (STI) Tops Q4 EPS by 2c
- Regions Financial (RF) Reports In-Line Q4 EPS
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!